GlassScriptPhysician profile
Seshan Subramanian
NPI 1083691950
$5,886.12
in general payments reported to CMS, 2019-2025
40 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $131 · 2021: $368 · 2022: $687 · 2023: $988 · 2024: $1,575 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,424 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,424.40 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,049.49 | 2021-2025 | Enhertu, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $516.40 | 2020-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $482.25 | 2022-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $346.58 | 2022-2025 | |
| Incyte Corporation | $338.71 | 2021-2025 | Jakafi |
| Pfizer INC. | $306.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $300.05 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Celgene Corporation | $238.01 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $232.98 | 2021-2024 | Lumakras, Prolia, Evenity |
| Janssen Biotech, INC. | $212.80 | 2022-2025 | Erleada, Akeega, Rybrevant |
| Array Biopharma INC | $186.08 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Astellas Pharma US INC | $173.88 | 2020-2025 | Xtandi |
| Daiichi Sankyo INC. | $154.16 | 2024-2025 | Enhertu, Datroway |
| Genzyme Corporation | $134.02 | 2019-2025 | |
| Tempus Ai, INC | $128.33 | 2024-2025 | Xt Cdx |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seshan Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.